Annual Drug Patent Expirations for GLEEVEC
Gleevec is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges.
Drug patent litigation for GLEEVEC.
The generic ingredient in GLEEVEC is imatinib mesylate. One supplier is listed for this compound. Additional details are available on the imatinib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
